RxDoctor Payments Data

Ashela Bean, DO

Internal Medicine · Webster, TXNPI 1255795027

Payments from drug & device makers

$1,118in general payments, 2019–2025

Across 40 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$411
  • AstraZeneca$165
  • Dexcom, Inc.$118
  • Medtronic$112
  • Exact Sciences$104
  • Lilly USA, LLC$65
  • plus $144 from 5 others

What the payments were for

  • Food & beverage$1,118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,118 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,838
Medicare patients
39
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$75,274
JanuviaSitagliptin Phosphate32$25,552
JardianceEmpagliflozin20$20,186
EliquisApixaban15$16,266
TrulicityDulaglutide13$12,283
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,578
Albuterol Sulfate HfaAlbuterol Sulfate51$1,906
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,793
Atorvastatin Calcium246$1,586
Gabapentin62$1,393
Amlodipine Besylate194$979
Lisinopril109$659
Chlorthalidone30$627
Fluticasone Propionate39$578
Metformin Hcl103$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$411$75,27473 claims
PfizerEliquis$29$16,26615 claims
Lilly USA, LLCTrulicity$65$12,28313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →